Restylane® Marks Heritage Milestone
FORT WORTH, Texas - June 10, 2016 - Galderma, a global leader focused on medical solutions in skin health, is proud to celebrate the significant milestone of the 20th global anniversary of the Restylane® portfolio of products. One of the world's most studied wrinkle fillers, Restylane has been used in more than 65 countries worldwide with over 28 million treatments administered globally.
"The launch of the Restylane dermal filler in Europe in 1996 and in the United States in 2003 helped to change the aesthetic landscape. It quickly became a household name, and sparked a shift in how many of my patients approached facial aging," said Chicago-based physician Steve Dayan. "This anniversary not only celebrates 20 years of being a great option for men and women who want natural-looking results, but also serves as a proof point for how well-placed my trust is in the long track record of safety and efficacy of Restylane products in my practice."
After more than two decades of research, the complete line of Restylane fillers - including Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine and Restylane® Silk - have well-defined safety profiles. With six major product approvals and four different indications, the Restylane family of products continues to deliver effective and proven aesthetic solutions to healthcare professionals and their patients allowing specialists to customize a treatment plan that's right for each individual.
Innovative Syringe Delivers Enhanced Ergonomics and Safety Building on the heritage of the milestones in the last 20 years, Galderma is committed to continuing its leadership role of Restylane innovation in the future.
"All of us at Galderma are inspired by this significant milestone for Restylane," said Kelly Huang, PhD, Vice President and General Manager, Aesthetic & Corrective Business Unit, Galderma, U.S. "The combination of the proven safety history backed by over 28 million treatments globally and a continual pipeline of innovation, such as our enhanced syringe introduction for key Restylane products, is a strong foundation for the Restylane brands to continue to support the goals of healthcare professionals and patients now and in the future."
For more information about the Restylane family of products at our practice, visit Dr. Stompro and Dr. Cheng's Restylane information page at: http://www.plasticsurgery1.com/non-surgical-services/injectables/restylane/
Or visit the company website at: www.RestylaneUSA.com